ARS Pharmaceuticals Inc. (SPRY)
12.63
0.14 (1.12%)
At close: Mar 31, 2025, 1:48 PM
ARS Pharmaceuticals Cash Flow Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
| Net Income | 8M | -54.37M | -34.68M | -20.24M | -1.06M | -23.97M | -17.58M |
| Depreciation & Amortization | 79K | 73K | 319K | 6K | 6K | 1.55M | 1.42M |
| Stock-Based Compensation | 14.53M | 9.23M | 5.84M | 2.83M | 3.54M | n/a | n/a |
| Other Working Capital | n/a | -4.55M | -2.47M | -6.39M | 4.67M | -714K | -946K |
| Other Non-Cash Items | -9.06M | -6.88M | 1.2M | 207K | 121K | -699K | 2.04M |
| Deferred Income Tax | n/a | n/a | n/a | -4K | 1K | n/a | n/a |
| Change in Working Capital | n/a | -7.33M | -12.75M | -356K | 6.46M | 3.3M | -433K |
| Operating Cash Flow | 13.55M | -59.27M | -40.08M | -17.56M | 9.07M | -18.9M | -16.88M |
| Capital Expenditures | -563K | -175K | -199K | -55K | -917K | -96K | -449K |
| Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Purchase of Investments | -356.04M | -272M | n/a | -65.11M | n/a | n/a | n/a |
| Sales Maturities Of Investments | 258M | 185M | n/a | n/a | n/a | n/a | n/a |
| Other Investing Acitivies | -7.5M | n/a | n/a | 65.11M | n/a | n/a | n/a |
| Investing Cash Flow | -106.1M | -87.18M | -199K | -55K | -917K | -96K | -449K |
| Debt Repayment | n/a | n/a | -8.68M | -1.82M | 5M | 8.59M | -852K |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 72.4M | 6.9M | 199.41M | 54.98M | 99K | n/a | n/a |
| Financial Cash Flow | 72.4M | 6.9M | 190.73M | 53.16M | 5.1M | 8.61M | 19.4M |
| Net Cash Flow | -20.15M | -139.55M | 150.46M | 35.54M | 14.17M | -10.18M | 2.08M |
| Free Cash Flow | 12.98M | -59.44M | -40.28M | -17.62M | 8.15M | -18.99M | -17.32M |